Tyvaso FDA Approval History
FDA Approved: Yes (First approved July 30, 2009)
Brand name: Tyvaso
Generic name: treprostinil
Dosage form: Inhalation Solution
Company: United Therapeutics Corporation
Treatment for: Pulmonary Hypertension
- Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.
- Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
Development Timeline for Tyvaso
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.